Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etrumadenant - Arcus Biosciences

Next Previous
X
Search
Drug Profile

Etrumadenant - Arcus Biosciences

Alternative Names: A2a/A2b adenosine receptor antagonist - Arcus Biosciences; AB 928; GS-0928

Latest Information Update: 17 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcus Biosciences
  • Developer Arcus Biosciences; Genentech; Gilead Sciences; Memorial Sloan-Kettering Cancer Center; Washington University School of Medicine
  • Class Amines; Antineoplastics; Nitriles; Pyridines; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Liposarcoma; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer
  • Phase I Cancer
  • No development reported Bladder cancer; Endometrial cancer; Gastrointestinal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Oesophageal cancer; Ovarian cancer; Renal cancer; Triple negative breast cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 18 Nov 2024 Arcus Biosciences completes the phase I ARC-4 trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in Taiwan, Singapore, South Korea (IV) (NCT03846310)
  • 30 Aug 2024 Arcus Biosciences completes the phase I/II trial in Prostate cancer (Combination therapy, Hormone refractory, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and Canada (PO) (NCT04381832)
  • 02 Jun 2024 Efficacy and adverse events data from the phase Ib/II ARC-9 trial in Colorectal cancer released by Gilead Sciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top